Navigation Links
Daniel K. Spiegelman Elected to Board of Directors of Omeros
Date:12/9/2009

SEATTLE, Dec. 9 /PRNewswire/ -- Omeros Corporation today announced that its Board of Directors has elected Daniel K. Spiegelman to serve on the Company's Board. Mr. Spiegelman has also been appointed to serve as Chairman of the Audit Committee.

"We are very pleased to welcome Dan to our Board and look forward to working with him," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "Dan brings a substantial depth and breadth of financial experience in public biotech companies. He will be a valuable asset to Omeros as we prepare to bring our products to market."

"I am excited to be joining Omeros' Board," stated Daniel Spiegelman. "The strength of the Company's management team and pipeline provide significant and multiple opportunities to advance science and improve the lives of patients. I look forward to contributing to the Company's success."

Mr. Spiegelman has over 25 years of executive management, finance and operations experience. He was senior vice president and chief financial officer at CV Therapeutics prior to and during its acquisition by Gilead earlier this year. Prior to that, he was employed by Genentech, where he served as Treasurer and held a number of other senior financial positions. Mr. Spiegelman also serves on the boards of directors and chairs the audit committees of Affymax, Cyclacel Pharmaceuticals and Oncothyreon, all publicly traded biopharmaceutical companies. He earned his M.B.A. from the Stanford Graduate School of Business and his B.A. in economics from Stanford University.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of pati
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Omnicell Selected by Nations Third Largest Public Healthcare System for Medication Management Systems
2. Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
3. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
4. Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries
5. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
6. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
7. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
8. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
9. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, today ... 28, 2015. Net sales for the first ... 1.4% compared with the first quarter of 2014.  This ... 6.0% decline related to foreign currency exchange.  In local ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9Henry Schein Reports Record First Quarter Results 10Henry Schein Reports Record First Quarter Results 11Henry Schein Reports Record First Quarter Results 12Henry Schein Reports Record First Quarter Results 13Henry Schein Reports Record First Quarter Results 14Henry Schein Reports Record First Quarter Results 15Henry Schein Reports Record First Quarter Results 16Henry Schein Reports Record First Quarter Results 17
... overall survival rate from,cancer now is lower in older ... in part because of a lack of access to ... a study by pediatric,oncologists at Children,s Hospital of Pittsburgh ... than 15 with cancer have,improved dramatically over the last ...
... Period -, EXTON, Pa., Jan. 15 ... been completed in the pivotal,Phase III multi-center, double-blind, ... the treatment of,nasolabial folds, or wrinkles (Studies IT-A-005 ... of the study., Isolagen also announced the ...
Cached Medicine Technology:Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 2Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 3Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies 2
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... New West Medicare is excited to ... to manage outpatient advanced imaging services for its members. ... its members are provided the right test at the ... with New West Medicare’s physicians and hospitals, Care to ... advanced imaging and provide an objective basis for informed ...
(Date:5/4/2015)... Sylvia Hawthorn-Deppen shared her experiences living with ... others in similar situations that they were not alone, in ... Discovery of New Energy” (published by Balboa Press). This year ... renewed press campaign. , “I have spent nearly 60 years ... says. “As an adolescent I got into trouble with an ...
(Date:5/4/2015)... Fast on the heels of Autism Awareness ... Allison Folmar, JD, join over 150 speakers in the ... Sunday, May 24, the conference presents "I Know You're ... interested in Ryan Hinds' recovery story? The book ... autism was written by Marcia Hinds, Ryan’s mom. ...
(Date:5/4/2015)... Sara Soulati, CEO of Global Cardio ... Los Angeles associated with the field of Enhanced External ... Sara Soulati Health For Life Program (SSHFLP). , The ... modification and disease prevention program. A provisional patent ... Patents and Trademarks Office and is now under review ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... chemically-modified version of a mitochondrial toxin long used to ... found to selectively inhibit two "survival proteins in ... step toward developing a molecularly-targeted drug that could eliminate ... therapy found in many types of cancers. ,scientists ...
... just how important it is for mothers-to-be to relax, by ... their offspring will develop cerebral palsy . ,Cerebral ... disability. ,Though the study was conducted on a ... sante et de la recherche medicale, the French public biomedical ...
... together to plug the site of injury in the form ... aggregation can block blood vessels and cause heart attack ... many molecules to platelet integrin alpha-IIb beta 3, and blockade ... clots. ,However, chronic use of oral drugs that ...
... for neuroblastoma that lands a one-two punch works best when ... of the first one, according to results of studies at ... tumor that arises from cells in the peripheral nervous system. ... by using the drug bevacizumab to block VEGF, a protein ...
... tobacco industrys deceptive practices have been aggressively quashed through ... Ibrahim , co-author of an analysis in the August ... ,In the article, Ibrahim tracks the rise and ... for the past 40 years. She chronicles industry strategies ...
... the long-standing claim that organic farming methods cannot produce ... can yield up to three times as much food ... on the same land. ,Researchers from the ... were almost equal on organic and conventional farms. ...
Cached Medicine News:Health News:Cell Toxin Inhibits Survival Protein in Cancer Cells 2Health News:Tumor Blood Flow can Improve Chemotherapy 2Health News:Tumor Blood Flow can Improve Chemotherapy 3Health News:Tobacco Industry Promotes Antismoking Campaigns 2Health News:Tobacco Industry Promotes Antismoking Campaigns 3Health News:Organic Farming can Feed the World, U-M Study Shows 2Health News:Organic Farming can Feed the World, U-M Study Shows 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: